155 related articles for article (PubMed ID: 4839098)
1. Parkinsonian syndromes. Treatment by association of L-dopa plus decarboxylase inhibitor.
Gauthier G; Juge O; Birchler A
Eur Neurol; 1974; 11(3):133-57. PubMed ID: 4839098
[No Abstract] [Full Text] [Related]
2. Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602.
Knutsson E; Mårtensson A
Scand J Rehabil Med; 1974; 6(2):89-93. PubMed ID: 4837060
[No Abstract] [Full Text] [Related]
3. Morphological and biochemical studies on liver biopsies of parkinsonian patients treated with levodopa and decarboxylase inhibitor.
Nevalainen T; Riekkinen P; Rinne UK; Sonninen V
Acta Neurol Scand; 1974; 50(1):122-30. PubMed ID: 4365556
[No Abstract] [Full Text] [Related]
4. L-dopa for parkinsonism.
Reveno WS; Bauer RB; Rosenbaum H
Geriatrics; 1973 Jan; 28(1):86-8. PubMed ID: 4683093
[No Abstract] [Full Text] [Related]
5. Effects of L-dopa alone and in combination with dopa decarboxylase inhibitors on the arterial pressure and heart rate of dogs.
Minsker DH; Scriabine A; Stokes AL; Stone CA; Torchiana ML
Experientia; 1971 May; 27(5):529-31. PubMed ID: 5132586
[No Abstract] [Full Text] [Related]
6. Treatment of Parkinsonism with a combination of levodopa and the decarboxylase inhibitor and RO 46-4602 (a comparison with levodopa treatment alone).
Dupont E; Hansen E; Melsens S; Parkenberg H; Holm P
Acta Neurol Scand Suppl; 1972; 51():115-7. PubMed ID: 4514334
[No Abstract] [Full Text] [Related]
7. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
Gattringer B; Steinhäusl H
Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
[No Abstract] [Full Text] [Related]
8. Plasma testosterone content of male patients with Parkinson's disease during L-dopa treatment with or without dopadecarboxylase inhibitor.
Pekkarinen A; Rinne UK; Salokangas R; Siirtola T; Sonninen V
Acta Neurol Scand Suppl; 1972; 51():129-30. PubMed ID: 4514339
[No Abstract] [Full Text] [Related]
9. [The therapeutic effect of L-dopa].
Groneberg P; Struppler A
Naturwissenschaften; 1972 Nov; 59(11):492-6. PubMed ID: 4657650
[No Abstract] [Full Text] [Related]
10. [10 years of L-DOPA therapy of Parkinson's syndrome].
Birkmayer W
Wien Klin Wochenschr; 1971 Apr; 83(13):221-7. PubMed ID: 4254333
[No Abstract] [Full Text] [Related]
11. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
Tissot R; de Ajuriaguerra J
Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
[No Abstract] [Full Text] [Related]
12. [Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor].
Fischer PA; Schneider E; Jacobi P; Maxion H
Med Welt; 1973 Nov; 24(45):1742-6. PubMed ID: 4768206
[No Abstract] [Full Text] [Related]
13. [Side effects occurring in the course of treatment of parkinsonism with L-dopa].
Kuran W
Neurol Neurochir Pol; 1973; 7(4):587-94. PubMed ID: 4583001
[No Abstract] [Full Text] [Related]
14. [Case reports of some mental disorders in parkinsonian patients treated with L-dopa].
Almici GM; Sbarbaro V
Minerva Med; 1974 Feb; 65(8):398-401. PubMed ID: 4820722
[No Abstract] [Full Text] [Related]
15. Treatment of Parkinsonism with a compound of L-dopa (Larodopa R) and a decarboxylase inhibitor (RO-46-4602).
Holmsen R; Kvan L; Presthus J; Thoresen GB
Acta Neurol Scand Suppl; 1972; 51():121-2. PubMed ID: 4514336
[No Abstract] [Full Text] [Related]
16. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
Christiani K; Möller WD
Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
[No Abstract] [Full Text] [Related]
17. Suppression by alpha-methyltyrosine of ethanol-induced locomotor stimulation: partial reversal by L-dopa.
Engel J; Strömbom U; Svensson TH; Waldeck B
Psychopharmacologia; 1974 Jul; 37(3):275-9. PubMed ID: 4153095
[No Abstract] [Full Text] [Related]
18. [Current treatment of Parkinson syndrome with L-dopa].
Gerstendbrand F; Gründig E; Musiol A
Pol Tyg Lek; 1972 May; 27(21):798-800. PubMed ID: 4555002
[No Abstract] [Full Text] [Related]
19. Dopa-decarboxylase inhibitors.
Lancet; 1973 May; 1(7810):979-80. PubMed ID: 4121597
[No Abstract] [Full Text] [Related]
20. Therapeutic uses and side effects of L-dopa.
Boshes B
Adv Intern Med; 1972; 18():219-49. PubMed ID: 4576081
[No Abstract] [Full Text] [Related]
[Next] [New Search]
